Effect of "lipid metabolism" related genotypes on the treatment response by PUFA add-on therapy for bipolar disorder
Not Applicable
- Conditions
- Bipolar disorder
- Registration Number
- JPRN-UMIN000023221
- Lead Sponsor
- Department of Psychiatry, Fujita Health University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
-Bipolar disorder (rapid cycling) diagnosed by DSM- -patients who are taking EPA/DHA -Allergy for EPA/DHA -metabolic syndrome at the enrollment -Side effect by EPA/DHA -High risk of hemorrhage -patients who received more than 3 types of antipsychotics or antidepressants -patients who received more than 3 types of antidepressants (exclude antidepressants which use only as hypnotics)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method "manic" and "depressive" phases (at enrollment)" Outcome: improve rate of YMRS and MADRS (at 12 week) "remission" (at enrollment) Outcome: recurrent rate (YMRS/MADRS >=13) 52 weeks follow up (first visit, 2w, 4w, every 4weeks thereafter)
- Secondary Outcome Measures
Name Time Method "manic" and "depressive" phases (at enrollment)" Response (50% reduction of YMRS/MADRS) and non-response rates Remission (YMRS/MADRS<=12) and non-remission rates CGI change at the final weeks RNA/Protein/lipid concentration (Cholesterol/HDL/LDL/TG, omega3 and omega 6 PUFAs)